Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232553 · ClinicalTrials.gov registry record · Phase 3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 996
- Enrollment target
- 20
- Study locations
NCT04232553 is a Phase 3 study of Crohn's Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 996 participants, below the 2,385-participant average among 105 other Crohn's Disease trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04232553, a Phase 3 study of Crohn's Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 996 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Conditions Studied
Interventions
- DRUG Mirikizumab
Study Locations (20)
Florida
- Gastroenterology Consultants of Clearwater - Clearwater
- Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
- IHS Health Research - Kissimmee
- Ezy Medical Research - Miami
- Care Access - Orlando - Orlando
- Gastroenterology Associates of Pensacola, PA - Pensacola
- Precision Clinical Research - Sunrise
- USF Health - Tampa
- Alliance Clinical Research of Tampa - Tampa
California
- Care Access - Gilroy - Gilroy
- Newport Huntington Medical Group - Huntington Beach
- California Medical Research Associates - Northridge
Arizona
- Research Solutions of Arizona - Litchfield Park
- Arizona Arthritis & Rheumatology Research, PLLC - Phoenix
Georgia
- Digestive Healthcare of Georgia - Atlanta
- Gastrointestinal Specialists of Georgia - Marietta
Alabama
- Digestive Health Specialists - Dothan
Connecticut
- Connecticut Clinical Research Institute - Bristol
Idaho
- Grand Teton Research Group - Idaho Falls
Indiana
- Qualmedica Research, LLC - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 996 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04232553
The ClinicalTrials.gov registry entry for NCT04232553 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 996 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,385-participant average among 105 other Crohn's Disease trials with a reported enrollment target (58% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Mirikizumab is the first listed.
NCT04232553 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04232553 about?
NCT04232553 is a clinical study titled "A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease". The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
What is the current status of trial NCT04232553?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 996 participants. The study started on 2020-06-22. Estimated completion is 2027-04.
What conditions does trial NCT04232553 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT04232553?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT04232553?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04232553 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.